NCT00809588View on ClinicalTrials.gov

Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF)

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 16, 2003

Primary Completion Date

September 30, 2016

Study Completion Date

February 25, 2020

Conditions
Melanoma
Interventions
BIOLOGICAL

Autologous, lethally irradiated melanoma cells

Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00809588 - Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) | Biotech Hunter | Biotech Hunter